Qelbree Hits Shelves; Schizophrenia-Related Cognitive Impairment Breakthrough

(MedPage Today) -- The newly approved viloxazine extended-release capsules (Qelbree), a new selective norepinephrine reuptake inhibitor for the treatment of attention-deficit hyperactivity disorder in patients ages 6 to 17, is now available in...